Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis.
Atsushi Nagayasu; Yusuke Miyazaki; Koshiro Sonomoto; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Hiroaki Tanaka; Yasuyuki Todoroki; Masanobu Ueno; Takafumi Aritomi; Yuya Fujita; Hidenori Sakai; Katsunori Suzuki; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology and therapy, Aug. 2025

Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: the FIRST registry.
Hiroki Kobayashi; Yusuke Miyazaki; Shingo Nakayamada; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ayako Yamaguchi; Yoshino Inoue; Yasuyuki Todoroki; Hiroko Miyata; Hiroaki Tanaka; Yoshihisa Fujino; Shintaro Hirata; Yoshiya Tanaka
Rheumatology (Oxford, England), May 2025

Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry.
Yusuke Miyazaki; Shingo Nakayamada; Hiroaki Tanaka; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Yasuyuki Todoroki; Yoshino Inoue; Masanobu Ueno; Yoshiya Tanaka
Rheumatology (Oxford, England), Apr. 2025

Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry.
Hidenori Sakai; Yusuke Miyazaki; Shingo Nakayamada; Satoshi Kubo; Kentaro Hanami; Shunsuke Fukuyo; Ayako Yamaguchi; Ippei Miyagawa; Masanobu Ueno; Hiroaki Tanaka; Yasuyuki Todoroki; Naoaki Ohkubo; Masashi Funada; Satsuki Matsunaga; Yoshiya Tanaka
Rheumatology (Oxford, England), Apr. 2025

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.
Ryuichiro Kanda; Yusuke Miyazaki; Shingo Nakayamada; Shunsuke Fukuyo; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Yurie Satoh-Kanda; Naoaki Ohkubo; Yasuyuki Todoroki; Hiroaki Tanaka; Masanobu Ueno; Atsushi Nagayasu; Yuya Fujita; Takafumi Aritomi; Katsuhide Kusaka; Hidenori Sakai; Satsuki Matsunaga; Hirotsugu Nohara; Yoshiya Tanaka
Rheumatology and therapy, Apr. 2025

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry.
Yusuke Miyazaki; Shingo Nakayamada; Hiroaki Tanaka; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ayako Yamaguchi; Ippei Miyagawa; Yurie Satoh-Kanda; Yasuyuki Todoroki; Yoshino Inoue; Masanobu Ueno; Yoshiya Tanaka
RMD open, Jan. 2025

Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.
Yusuke Miyazaki; Masashi Funada; Shingo Nakayamada; Koshiro Sonomoto; Hiroaki Tanaka; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ayako Yamaguchi; Ippei Miyagawa; Yasuyuki Todoroki; Masanobu Ueno; Yoshiya Tanaka
Rheumatology (Oxford, England), Sep. 2024

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study.
Koshiro Sonomoto; Shingo Nakayamada; Yoshihisa Fujino; Hiroko Miyata; Satoshi Kubo; Yuya Fujita; Yoshino Inoue; Satsuki Matsunaga; Shigeru Iwata; Kentaro Hanami; Yasuyuki Todoroki; Hiroko Yoshinari-Korekoda; Akio Kawabe; Ayako Yamaguchi; Masanobu Ueno; Yurie Satoh-Kanda; Ryuichiro Kanda; Masashi Funada; Naoaki Ohkubo; Katsuhide Kusaka; Shumpei Kosaka; Atsushi Nagayasu; Shunsuke Fukuyo; Masao Nawata; Yusuke Miyazaki; Mikiko Tokunaga; Kenichi Tanaka; Yosuke Okada; Yoshiya Tanaka
Rheumatology (Oxford, England), Aug. 2024

Selection of treatment regimens based on shared decision making after sustained remission in patients with rheumatoid arthritis,-The two-year results of the FREE-J study.
山口絢子; 山口絢子; 田中良哉
月刊リウマチ科, 2023

Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study.
Yoshiya Tanaka; Ayako Yamaguchi; Toshiaki Miyamoto; Kazuhide Tanimura; Hideyuki Iwai; Yuko Kaneko; Tsutomu Takeuchi; Koichi Amano; Naoki Iwamoto; Atsushi Kawakami; Miho Murakami; Norihiro Nishimoto; Tatsuya Atsumi; Takayuki Sumida; Koichiro Ohmura; Tsuneyo Mimori; Hisashi Yamanaka; Keishi Fujio; Yoshihisa Fujino; Kazuyoshi Saito; Kazuhisa Nakano; Shintaro Hirata; Shingo Nakayamada
Rheumatology (Oxford, England), Nov. 2022

DMARD de-escalation in patients with rheumatoid arthritis.
山口絢子; 山口絢子; 田中良哉
月刊リウマチ科, 2022

Erythrocyte sedimentation rate and CRP
山口絢子; 山口絢子; 田中良哉
日本臨床, 2022

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
Yusuke Miyazaki; Kazuhisa Nakano; Shingo Nakayamada; Satoshi Kubo; Shigeru Iwata; Kentaro Hanami; Shunsuke Fukuyo; Ippei Miyagawa; Ayako Yamaguchi; Akio Kawabe; Kazuyoshi Saito; Yoshiya Tanaka
Arthritis research & therapy, Jun. 2021

5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.
Ayako Yamaguchi; Shintaro Hirata; Satoshi Kubo; Shunsuke Fukuyo; Kentaro Hanami; Kazuhisa Nakano; Shingo Nakayamada; Kazuyoshi Saito; Yoshiya Tanaka
Modern rheumatology, Sep. 2020

The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study.
Takuya Hirai; Keigo Ikeda; Maki Fujishiro; Hiroshi Tsushima; Kunihiro Hayakawa; Satoshi Suzuki; Ayako Yamaguchi; Kazuhisa Nozawa; Shinji Morimoto; Yoshinari Takasaki; Hideoki Ogawa; Kenji Takamori; Naoto Tamura; Iwao Sekigawa
Clinical rheumatology, Jan. 2017

A re-evaluation of anti-NA-14 antibodies in patients with primary Sjögren's syndrome: Significant role of interferon-γ in the production of autoantibodies against NA-14.
Kaori Uomori; Kazuhisa Nozawa; Keigo Ikeda; Kentaro Doe; Yusuke Yamada; Ayako Yamaguchi; Maki Fujishiro; Mikiko Kawasaki; Shinji Morimoto; Kenji Takamori; Iwao Sekigawa; Edward K L Chan; Yoshinari Takasaki
Autoimmunity, Aug. 2016

CC motif chemokine ligand 13 is associated with rheumatoid arthritis pathogenesis.
Ayako Yamaguchi; Kazuhisa Nozawa; Maki Fujishiro; Mikiko Kawasaki; Fujihiko Suzuki; Kenji Takamori; Hideoki Ogawa; Yoshinari Takasaki; Iwao Sekigawa
Modern rheumatology, Sep. 2013

Inhibition of connective tissue growth factor ameliorates disease in a murine model of rheumatoid arthritis.
Kazuhisa Nozawa; Maki Fujishiro; Mikiko Kawasaki; Ayako Yamaguchi; Keigo Ikeda; Shinji Morimoto; Kazuhisa Iwabuchi; Mitsuaki Yanagida; Shouzo Ichinose; Megumi Morioka; Hideoki Ogawa; Kenji Takamori; Yoshinari Takasaki; Iwao Sekigawa
Arthritis and rheumatism, Jun. 2013

Estrogen inhibits apoptosis and promotes CC motif chemokine ligand 13 expression on synovial fibroblasts in rheumatoid arthritis.
Ayako Yamaguchi; Kazuhisa Nozawa; Maki Fujishiro; Mikiko Kawasaki; Kenji Takamori; Hideoki Ogawa; Iwao Sekigawa; Yoshinari Takasaki
Immunopharmacology and immunotoxicology, Oct. 2012

Regenerating gene (REG) 1 alpha promotes pannus progression in patients with rheumatoid arthritis.
Maki Fujishiro; Kazuhisa Nozawa; Mikiko Kawasaki; Ayako Yamaguchi; Kazuhisa Iwabuchi; Mitsuaki Yanagida; Fujihiko Suzuki; Keiji Miyazawa; Hirokazu Fukui; Kazuo Kaneko; Hideoki Ogawa; Kenji Takamori; Yoshinari Takasaki; Iwao Sekigawa
Modern rheumatology, Apr. 2012

A new hypothesis of the possible mechanisms of gender differences in systemic lupus erythematosus.
Iwao Sekigawa; Maki Fujishiro; Ayako Yamaguchi; Mikiko Kawasaki; Akihiro Inui; Kazuhisa Nozawa; Yoshinari Takasaki; Kennji Takamori; Hideoki Ogawa
Clinical and experimental rheumatology, 2010

Fluctuations in the gene expression of peripheral blood mononuclear cells between the active and inactive phases of systemic lupus erythematosus.
Mikiko Kawasaki; Maki Fujishiro; Ayako Yamaguchi; Kazuhisa Nozawa; Hiroshi Kaneko; Yoshinari Takasaki; Kenji Takamori; Hideoki Ogawa; Iwao Sekigawa
Clinical and experimental rheumatology, 2010

FREE-J studyにおける患者とのshared decision makingによるRA寛解時の治療選択
山口 絢子, 田中 良哉
リウマチ科, Oct. 2023, Reviewed, No invitation
Lead

【関節リウマチの治療の現状と問題点】治療薬剤の減量と休薬
山口絢子, 田中良哉
リウマチ科, Apr. 2022, Reviewed, No invitation
Lead

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
Miyazaki Yusuke, Nakano Kazuhisa, Nakayamada Shingo, Kubo Satoshi, Iwata Shigeru, Hanami Kentaro, Fukuyo Shunsuke, Miyagawa Ippei, Yamaguchi Ayako, Kawabe Akio, Saito Kazuyoshi, Tanaka Yoshiya
Arthritis research & therapy, Jun. 2021, Reviewed, No invitation

5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.
Yamaguchi Ayako, Hirata Shintaro, Kubo Satoshi, Fukuyo Shunsuke, Hanami Kentaro, Nakano Kazuhisa, Nakayamada Shingo, Saito Kazuyoshi, Tanaka Yoshiya
Modern rheumatology, Jan. 2020, Reviewed, No invitation
Lead

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry.
Miyazaki Yusuke, Nakayamada Shingo, Tanaka Hiroaki, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Yamaguchi Ayako, Miyagawa Ippei, Satoh-Kanda Yurie, Todoroki Yasuyuki, Inoue Yoshino, Ueno Masanobu, Tanaka Yoshiya
RMD open, Jan. 2025, Reviewed, No invitation

Efficacy, safety, and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry.
Sakai Hidenori, Miyazaki Yusuke, Nakayamada Shingo, Kubo Satoshi, Hanami Kentaro, Fukuyo Shunsuke, Yamaguchi Ayako, Miyagawa Ippei, Ueno Masanobu, Tanaka Hiroaki, Todoroki Yasuyuki, Ohkubo Naoaki, Funada Masashi, Matsunaga Satsuki, Tanaka Yoshiya
Rheumatology (Oxford, England), Sep. 2024, Reviewed, No invitation

Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST study.
Miyazaki Yusuke, Nakayamada Shingo, Tanaka Hiroaki, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Miyagawa Ippei, Yamaguchi Ayako, Todoroki Yasuyuki, Inoue Yoshino, Ueno Masanobu, Tanaka Yoshiya
Rheumatology (Oxford, England), Jun. 2024, Reviewed, No invitation

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study.
Sonomoto Koshiro, Nakayamada Shingo, Fujino Yoshihisa, Miyata Hiroko, Kubo Satoshi, Fujita Yuya, Inoue Yoshino, Matsunaga Satsuki, Iwata Shigeru, Hanami Kentaro, Todoroki Yasuyuki, Yoshinari-Korekoda Hiroko, Kawabe Akio, Yamaguchi Ayako, Ueno Masanobu, Satoh-Kanda Yurie, Kanda Ryuichiro, Funada Masashi, Ohkubo Naoaki, Kusaka Katsuhide, Kosaka Shumpei, Nagayasu Atsushi, Fukuyo Shunsuke, Nawata Masao, Miyazaki Yusuke, Tokunaga Mikiko, Tanaka Kenichi, Okada Yosuke, Tanaka Yoshiya
Rheumatology (Oxford, England), Nov. 2023, Reviewed, No invitation

Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.
Miyazaki Yusuke, Funada Masashi, Nakayamada Shingo, Sonomoto Koshiro, Tanaka Hiroaki, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Yamaguchi Ayako, Miyagawa Ippei, Todoroki Yasuyuki, Ueno Masanobu, Tanaka Yoshiya
Rheumatology (Oxford, England), Sep. 2024, Reviewed, No invitation

Predictors of the effectiveness to first-line CTLA4-Ig in patients with rheumatoid arthritis: the FIRST registry.
Kobayashi Hiroki, Miyazaki Yusuke, Nakayamada Shingo, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Yamaguchi Ayako, Inoue Yoshino, Todoroki Yasuyuki, Miyata Hiroko, Tanaka Hiroaki, Fujino Yoshihisa, Hirata Shintaro, Tanaka Yoshiya
Rheumatology (Oxford, England), May 2025, Reviewed, No invitation

Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study.
Tanaka Yoshiya, Yamaguchi Ayako, Miyamoto Toshiaki, Tanimura Kazuhide, Iwai Hideyuki, Kaneko Yuko, Takeuchi Tsutomu, Amano Koichi, Iwamoto Naoki, Kawakami Atsushi, Murakami Miho, Nishimoto Norihiro, Atsumi Tatsuya, Sumida Takayuki, Ohmura Koichiro, Mimori Tsuneyo, Yamanaka Hisashi, Fujio Keishi, Fujino Yoshihisa, Saito Kazuyoshi, Nakano Kazuhisa, Hirata Shintaro, Nakayamada Shingo
Rheumatology (Oxford, England), Feb. 2022, Reviewed, No invitation

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.
Kanda Ryuichiro, Miyazaki Yusuke, Nakayamada Shingo, Fukuyo Shunsuke, Kubo Satoshi, Miyagawa Ippei, Yamaguchi Ayako, Satoh-Kanda Yurie, Ohkubo Naoaki, Todoroki Yasuyuki, Tanaka Hiroaki, Ueno Masanobu, Nagayasu Atsushi, Fujita Yuya, Aritomi Takafumi, Kusaka Katsuhide, Sakai Hidenori, Matsunaga Satsuki, Nohara Hirotsugu, Tanaka Yoshiya
Rheumatology and therapy, Mar. 2025, Reviewed, No invitation

Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis.
Nagayasu Atsushi, Miyazaki Yusuke, Sonomoto Koshiro, Kubo Satoshi, Miyagawa Ippei, Yamaguchi Ayako, Tanaka Hiroaki, Todoroki Yasuyuki, Ueno Masanobu, Aritomi Takafumi, Fujita Yuya, Sakai Hidenori, Suzuki Katsunori, Nakayamada Shingo, Tanaka Yoshiya
Rheumatology and therapy, Aug. 2025, Reviewed, No invitation

The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study.
Hirai Takuya, Ikeda Keigo, Fujishiro Maki, Tsushima Hiroshi, Hayakawa Kunihiro, Suzuki Satoshi, Yamaguchi Ayako, Nozawa Kazuhisa, Morimoto Shinji, Takasaki Yoshinari, Ogawa Hideoki, Takamori Kenji, Tamura Naoto, Sekigawa Iwao
Clinical rheumatology, Jan. 2017, Null, Null

赤沈、CRP
山口絢子, 田中良哉, Contributor
日本臨床社, Apr. 2022, Reviewed